Featuring perspectives from Dr Stephen V Liu and Dr Charles Rudin, including the following topics:

• Introduction (0:00)
• Case 1: Adjuvant Systemic Therapy? (1:15)
• Case 2: Lambert-Eaton Syndrome and Other Paraneoplastic Syndromes (4:16)
• Case 3: Small Cell Transformation of EGFR-Mutant Non-Small Cell Lung Cancer (9:54)
• Case 4: Trilaciclib in Extensive-Stage Disease (13:50)
• Comments: ASCO and Other Recent Datasets (18:05)
• Case 5: Short Disease-Free-Interval with Brain Metastases After Chemoradiation Therapy/Durvalumab … Lurbinectedin? (39:34)
• Case 6: Tarlatamab After Rapid Disease Progression on Chemotherapy/Atezolizumab (44:33)
• Case 7: Immune Effector Cell-Associated Neurotoxicity Syndrome on Tarlatamab with Brain Metastases (48:54)
• Case 8: Bispecific T-Cell Engager with Lurbinectedin on Protocol (56:38)

CME information and select publications

Featuring an interview with Dr Shannon N Westin, including the following topics:

• Biomarker testing and utility in ovarian cancer (OC) (0:00)
• Selection of a PARP inhibitor for the treatment of OC (9:18)
• Addition of immunotherapy to up-front treatment of OC (15:50)
• Utility of minimal residual disease and circulating tumor DNA assays in OC (17:10)
• Selection of treatment for recurrent OC (21:46)
• Clinical decision-making involved with PARP inhibitors for endometrial cancer (EC) (28:22)
• Adjuvant therapy for EC (32:28)
• Utility of lenvatinib/pembrolizumab in EC (35:08)
• Clinical findings supporting the potential use of selinexor for EC (39:42)
• Key findings involving trastuzumab deruxtecan (T-DXd) for HER2-positive gynecologic cancers (43:22)
• Management of adverse effects associated with T-DXd (49:49)

CME information and select publications

Featuring an interview with Dr Jacob Sands, including the following topics:

• TROPION-Lung05 Trial: Datopotamab Deruxtecan for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Actionable Genomic Alterations (0:00)
  • Sands J et al. Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: Results from the phase II TROPION-Lung05 study. J Clin Oncol 2025;43(10):1254-65. Abstract
• Phase III Randomized Clinical Trial Data with TROP2-Targeting Antibody-Drug Conjugates for Previously Treated Advanced NSCLC (6:52)
  • Ahn M-J et al. Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: The randomized, open-label phase III TROPION-Lung01 study. J Clin Oncol 2025;43(3):260-72. Abstract
  • Reinmuth N et al. Longer follow-up for survival and safety from the EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel in patients (pts) with metastatic non-small cell lung cancer (mNSCLC). ASCO 2025;Abstract 8599.
  • Paz-Ares LG et al. Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1 inhibitors (IO): Primary results from the phase 3 EVOKE-01 study. ASCO 2024;Abstract LBA8500.
• Evaluating TROP2 Expression Levels Through Normalized Membrane Ratio of TROP2 in the TROPION-Lung01 Trial (12:26)
  • Garassino MC et al. Normalized membrane ratio of TROP2 by quantitative continuous scoring is predictive of clinical outcomes in TROPION-Lung01. WCLC 2024;Abstract PL02.11.

CME information and select publications